Fig. 1



VEGF
ANG-2
VH
VH
VL
CH1
CL
VL
CL
CH1
Bivalent,
bispecific
antibody
CH2
CH2
CH3
CH3

Fig. 2a



ANG-2
VEGF
VH
VH
CH1
CH1
VL
VL
CL
CL
CH2
peptide linker
"Hole"-CH3
"Knobs"-CH3

Fig. 2b



ANG-2
VEGF
VL
VH
CH1
CH1
VH
VL
CL
CL
CH2
peptide linker
"Hole"-CH3
"Knobs"-CH3

Fig. 2c



ANG-2
VEGF
VH
VH
CL
CH1
VL
VL
CH1
CL
CH2
peptide linker
"Hole"-CH3
"Knobs"-CH3

Fig. 3



Simultaneous Binding of XMAb to hVEGF and hAng-2
XMA b 10µg/ml
RU
700
600
500
400
300
200
100
0
-100
-100
0
100
200
300
400
500
600
700
800
s
Time (0 = baseline)

Fig. 4




Fig. 5




Fig. 6



vessel area (%)
14.0
12.0
10.0
8.0
6.0
4.0
2.0
0.0
PBS + Vehicle
VEGF + Vehicle (300ng) day 3
VEGF + XMAb1 (10mg/kg)
PBS + Vehicle
VEGF + Vehicle (300ng) day 5
VEGF + XMAb1 (10mg/kg)

Fig. 7



Mean +/- SEM; n=6
vessel area (%)
12,00
10,00
8,00
6,00
4,00
2,00
0,00
PBS
VEGF (300ng)
VEGF + ANG2i-LC06 (10mg/kg)
VEGF + bevacizumab (10mg/kg)
VEGF + XMab1 (10mg/kg)
VEGF + ANG2i-LC06 (10mg/kg) + bevacizumab (10mg/kg)
day 3

Fig. 8



ANG2_PZ_COLO205_015; mean +/- SEM; n=10
Group 1: Xolair 10 mg/kg i.p.;
Group 2: ANG2i-LC06 10 mg/kg i.p.;
Group 3: Avastin 10 mg/kg i.p.;
Group 4: ANG2i-LC06 10 mg/kg i.p.; Avastin 10 mg/kg i.p.;
Group 6: Xmab1 10 mg/kg i.p.;
Tumor volume [mm3]
600,0
500,0
400,0
300,0
200,0
100,0
0,0
13
18
23
28
33
38
43
48
Study Day

Fig. 9



ANG2_PZ_COLO205_015A; mean +/- SEM; n=10
Group 1: Xolair 10 mg/kg i.p.;
Group 2: ANG2i-LC06 10 mg/kg i.p.;
Group 3: Avastin 10 mg/kg i.p.;
Group 4: Avastin 10 mg/kg i.p.; ANG2i-LC06 10 mg/kg i.p.;
Group 6: Xmab1 10 mg/kg i.p.;
Tumor volume [mm3]
1200,0
1000,0
800,0
600,0
400,0
200,0
0,0
33
38
43
48
53
58
63
Study Day

Fig. 10



ANG2_PZ_KPL-4_005; mean +/- SEM; n=10
Group 1: Xolair 10 mg/kg i.p.;
Group 2: ANG2i-LC06 10 mg/kg i.p.;
Group 3: Avastin 10 mg/kg i.p.;
Group 4: ANG2i-LC06 10 mg/kg i.p.; Avastin 10 mg/kg i.p.;
Group 6: Xmab1 10 mg/kg i.p.;
Tumor volume [mm3]
600,0
500,0
400,0
300,0
200,0
100,0
0,0
Study Day
36
41
46
51
56
61
66
71
76

Fig. 11




ANG2_PZ_KPL-4_005A; mean +/- SEM; n=10
Group 1: Xolair 10 mg/kg i.p.;
Group 2: ANG2i-LC06 10 mg/kg i.p.;
Group 3: Avastin 10 mg/kg i.p.;
Group 4: ANG2i-LC06 10 mg/kg i.p.; Avastin 10 mg/kg i.p.;
Group 6: XMab1 10 mg/kg i.p.;
Tumor volume [mm3]
450,0
400,0
350,0
300,0
250,0
200,0
150,0
100,0
50,0
0,0
36
41
46
51
56
61
66
Study Day

Fig. 12


ANG2_PZ_N87_004; mean +/- SEM
Vehicle
Avastin 10 mg/kg
ANG2i- LC06 10mg/kg
Xmab1 10mg/kg
Tumor volume [mm3]
900,0
800,0
700,0
600,0
500,0
400,0
300,0
200,0
100,0
0,0
0
10
20
30
40
50
60
70
80
90
Study Day